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1. Introduction
Sudden cardiac death (SCD) is a major cause of death in the USA and accounts for almost half
of all cardiovascular deaths. The estimated annual incidence of SCD in the USA stands at
300,000 to 350,000. A significant fraction of the patients who die from SCD have underlying
cardiovascular pathology, most commonly some form of cardiomyopathy but, often the
disease remains unrecognized presenting with SCD as the first event. Ischemic heart disease
is overwhelmingly the commonest cause of SCD but other forms of cardiomyopathy become
more important cause of SCD in younger population. Although the patients with cardiomy‐
opathy account for a small fraction of population burden of SCD, a subset of these patients are
at high risk and this rationalizes aggressive preventive strategy in them (figure 1). Lower
prevalence of ischemic heart disease in younger population makes other forms of cardiomy‐
opathy more important in that population. Moreover, the relative contribution of SCD in the
population has changed as the epidemiology, natural course and outcomes of lifestyle related
cardiovascular diseases, particularly ischemic heart disease, have changed. In this chapter we
will review sudden cardiac death in patients with cardiomyopathies focusing on epidemiology
and risk stratification of SCD, and approaches for primary and secondary prevention strategies
in them.
2. Sudden cardiac death and various forms of cardiomyopathy
Most cardiomyopathies with primary myocardial pathology predispose to sudden cardiac
death. These include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM),
left ventricular noncompaction and arrhythmogenic right ventricular cardiomyopathy
(ARVC). Apart from the primary pathologies involving the myocardium, various other
conditions can affect the myocardium secondarily due to myocardial stress, ischemia and
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infiltration. These conditions though not strictly classifiable as cardiomyopathies, but are
important and common causes of SCD in the setting of myocardial dysfunction. They include
ischemic heart disease, hypertension, valvular heart disease, and myocardial involvement
with conditions like sarcoidosis, amyloidosis.
3. Etiopathogenesis and pathophysiology of sudden cardiac death
The commonest mechanism of SCD is a ventricular arrhythmia, most often ventricular
tachycardia leading to vemntricular fibrillation. This accounts for 75-80% of all SCDs; the
remainder are the result of bradyarrhythmias. [1] Bradyarrhythmias including high grade AV
block and sinus node dysfunction may potentially be a mechanism of sudden death in
cardiomyopathies. However, assessing the exact electrophysiological mechanism of sudden
death may be complex since ventricular fibrillation may arise as an aftermath of a bradyar‐
rhythmia. Futhermore patients having suffered a VF arrest may be found to be in asystole (the
end stage of all arrhythmic sudden death) when first coming to medical attention, so both
mechanisms may be involved either as an initiator or as perpetuator in the event of sudden
death. In the Implanted Cardioverter Defibrillator (ICD) era with aborted sudden deaths due
to ICD shocks, bradyarrhythmic mechanisms of sudden death may be masked effectively by
back up bradycardia pacing by the ICDs.
Ventricular arrhythmias associated with cardiomyopathies result from primary electrical
defects inherent to the cardiomyopathy and activation of the neuro-humoral system in the
Figure 1. Absolute numbers of events and event rates of SCD in the general population and in specific subpopulations
over 1 y. General population refers to unselected population age greater than or equal to 35 y, and high-risk sub‐
groups to those with multiple risk factors for a first coronary event. Clinical trials that include specific subpopulations
of patients are shown in the right side of the figure. AVID _ Antiarrhythmics Versus Implantable Defibrillators; CASH _
Cardiac Arrest Study Hamburg; CIDS _ Canadian Implantable Defibrillator Study; EF _ ejection fraction; HF _ heart fail‐
ure; MADIT _ Multicenter Automatic Defibrillator Implantation Trial; MI _ myocardial infarction; MUSTT _ Multicenter
UnSustained Tachycardia Trial; SCD-HeFT _ Sudden Cardiac Death in Heart Failure Trial. (Adapted with permission
from reference 165)
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body as a compensatory hemodynamic mechanism. The efficacy of neuro-humoral blockers
like beta-blocker and renin-angiotensin-aldosterone axis blockers in effectively reducing the
risk of sudden cardiac death in cardiomyopathy, and relation of the risk of sudden cardiac
death to degree of hemodynamic jeopardy with cardiomyopathy suggest the latter mechanism.
In the following sections we will discuss the current knowledge of mechanisms of sudden
death in various forms of cardiomyopathies.
3.1. Ischemic cardiomyopathy
Ischemic cardiomyopathy is by far the most common cardiomyopathy leading to SCD
Commonest cause of SCD in these patients is ventricular tachyarrhythmia. Beyond the early
post-MI period, when recurrent MI and associated complications (mechanical and arrhythmic)
are more likely, almost three-fourth of patient deaths among those with prior MI (more than
three months old) and LV dysfunction are sudden and presumably arrhythmic, most likely
due to ventricular arrhythmias. [2] Susceptibility to ventricular arrhythmia in these patients
has multiple mechanisms. Scar resulting from myocardial infarction provides substrate for
reentrant ventricular tachycardia. Re-entry circuits involve areas of residual viable relatively
slowly conducting myocardial tissue inside the scars. These tracks of slowly conducting
myocardial tissue inside a scar, called isthmus, connecting two healthy or relatively healthy
areas form a full circuit for re-entrant arrhythmia. Patients with larger myocardial scar are
more likely to have reentrant circuit. [3] Moreover, larger scars also lead to more ventricular
remodeling and LV dysfunction, leading to activation of compensatory neuro-humoral factors
in the setting of left ventricular dysfunction and heart failure. These factors lead to changes in
repolarization and conduction properties of myocardial cells and abnormalities in intracellular
calcium homeostasis which are potentially arrhythmogenic by promoting triggered activity
and facilitating reentry. [4] Moreover, patients with ischemic cardiomyopathy have areas of
ischemic myocardium which predispose to the arrhythmia by changes in the myocyte
automaticity, excitability and refractoriness leading to dispersion of repolarization. The border
zones of the myocardial scars are important substrates for arrhythmia as they are composed
of fibrotic tissue as well as viable myocardium which are often ischemic. Heterogeneity of
infarct tissue as assessed by magnetic resonance imaging has been shown to predispose to
arrhythmia. Additionally, myocardial infarction leads to disturbances in the autonomic
innervation of the myocardium in the area surrounding the post-infarct scar which makes the
surrounding myocardium more susceptible to arrhythmia due to prolongation of refractory
periods in the denervated myocardium. [5] Apart from these, a patient with ischemic heart
disease is predisposed to SCD due to acute coronary syndrome.
3.2. Hypertrophic cardiomyopathy
Studies of HCM patients with ICDs have suggested that ventricular arrhythmias are the major
causes of SCD in this group of patients, [6], [7] although availability of back up pacing for
bradyarrhythmia precludes the ability of an ICD study to exclude the possibility of a bradyar‐
rhythmic etiology. [6] Bradyarrhythmias are, however, reported rarely in HCM so this seems
an unlikely possibility. Multiple pathologic, molecular and physiologic mechanisms could
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contribute to the causation of ventricular arrhythmias in patients with HCM. HCM is charac‐
terized pathologically by hypertrophied myocardium along with increased fibrosis and
myocardial disarray (figure 2). [8-10] Apart from these histopathological features that predis‐
pose to ventricular arrhythmias, there are also abnormalities of calcium handling at molecular
level. Cardiomyocytes in patients with systolic and diastolic heart failure have impaired ability
of calcium cycling due to altered expression and phosphorylation of sarcoplasmic calcium
ATPase 2(SERCA 2) and ryanodine receptor 2, key proteins involved in intracellular calcium
handling. [11], [12] Perturbed calcium fluxes have also been seen in HCM. [13], [14] Inefficient
energy utilization in some of the HCM associated mutations of troponin lead to insufficient
energy for the cardiomyocytes to maintain cellular calcium hemostasis, leading to increased
risk of arrhythmia especially during exercise. [15], [16] Microvascular dysfuction with
myocardial ischemia along with increased energy needs is another important factor contribu‐
ting to the arrhythmogenicity in HCM. [17], [18] Left ventricular outflow tract obstruction
(LVOTO) and altered systolic blood pressure response to exercise may mechanistically
predispose to SCD by electromechanical dissociation and demand ischemia. Hence arrhyth‐
mogenic substrates in HCM potentially include altered cellular handling of calcium, with
myocardial ischemia, patchy myocardial fibrosis and hypertrophy maintaining the arrhyth‐
mias. Moreover, presence of systolic or diastolic heart failure itself may contribute to the risk
by neuro-humoral activation. Apart from these intrinsic predispositions to arrhythmogenesis
in the natural course of disease, there has been recent concern of iatrogenic arrhythmias in
patients undergoing alcohol septal ablation, which leaves a large ventricular septal scar
predisposing to scar-related re-entrant ventricular arrhythmias. [19]-[21]
Figure 2. Photomicrographs showing hematoxyline and eosin-stained section with florid myocyte disarray and fibrosis
in familial HCM. Disarray is characterized by hypertrophic myocytes with enlarged and pleomorphic nuclei aligned at
odd angles to one another (panel A). Photomicrograph showing Masson’s trichrome stain with marked increase in
interstitial fibrosis, a hallmark of HCM (panel B). Adapted with permission from chapter ‘Cardiomyopathy’ by Sian
Hughes from the book ‘Cardiac Pathololgy: A Guide to Current Practice’ eds’ S. Kim Suvarna ISBN:
978-1-4471-2406-1 (Print) 978-1-4471-2407-8 (Online) (Springer).
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3.3. Arrhythmogenic cardiomyopathy
The hallmark of arrhythmogenic cardiomyopathy (previously called arrhythmogenic right
ventricular cardiomyopathy) is a defect in cell-cell adhesion caused by genetic defects most
commonly affecting the desmosomal proteins. Such defects lead to myocyte loss with fibrofatty
replacement of the myocardial tissue (figure 3), most commonly involving the right ventricle,
with left ventricular and biventricular involvement less commonly. This provides a substrate
for ventricular tachycardia from re-entry around the fibrous scar. [22] Reports of ventricular
arrhythmia in subjects harboring the genes of arrhythmogenic cardiomyopathy even in the
absence of detectable histopathological and MRI changes in the myocardium suggest an
additional electrical substrate distinct from simple reentry involving perhaps intracellular
signaling process or heterogeneity in conduction. Gap junction remodeling with paucity of
gap junctions in the myocardial cells of affected patients may also provide a substrate for
arrhythmia. [23]
Figure 3. Fibroadipose infiltration of the right ventricle, seen in the inset macroscopically top right, arrowed. Histology
shows the adipose and fibrous tissue replacement of the myocyte architecture (hematoxylin & eosin). Adapted with
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permission from chapter ‘Cardiomyopathy’ by Sian Hughes from the book ‘Cardiac Pathololgy: A Guide to Cur‐
rent Practice’ eds’ S. Kim Suvarna ISBN: 978-1-4471-2406-1 (Print) 978-1-4471-2407-8 (Online) (Springer).
3.4. Dilated cardiomyopathy
Dilated cardiomyopathy is characterized by loss of myocardial cells with interstitial, perivascu‐
lar and replacement fibrosis, which provide an arrhythmogenic substrate (figure 4). [24], [25]
Frequently the reentry circuits of these arrhythmias exit on the epicardial aspect of the myocar‐
dium, as distinct from ischemic cardiomyopathy where endocardial circuits are the rule. [25] This
is related to the differences in the pathogenetic mechanism of scar formation in the two groups
of patients, patients with ischemic cardiomyopathy having predisposition to endocardial scar
due to subendocardial ischemia and acute coronary events, while patients with dilated cardiomy‐
opathy having epicardial scar more often than ischemic cardiomyopathy. This also has implica‐
tions on therapeutic approach as patients with nonischemic cardiomyopathy with VT frequently
require epicardial approach for catheter ablation. [26] Arrhythmic events occurring in patients
with idiopathic dilated cardiomyopathy are nonsustained and sustained VT and ventricular
fibrillation in addition to isolated ventricular ectopy. [27], [28] Bundle branch reentry VT is
relatively commoner form of VT in patients with dilated cardiomyopathy, constituting 6-11% of
patients referred for catheter mapping of monomorphic VT. [26], [29] Spontaneous sustained VT
is rare in DCM and this diagnosis should raise the suspicion of other types of cardiomyopa‐
thies that do commonly cause scar related ventricular arrhythmias, including sarcoidosis, Chagas
disease and left dominant arrhythmogenic cardiomyopathy. Spontaneous sustained VTs are
caused by scar-related related reentry or bundle branch reentry. [25], [29] Neurohumoral
activation, myocardial stretch secondary to mechanical overload and electrolyte disturbance all
can contribute to arrhythmogenesis by a non-reentrant mechanism facilitating focal mecha‐
nisms of arrhythmogenesis like triggered activity and focal automaticity. [28]
3.5. Left Ventricular noncompaction
Left ventricular noncompaction is a recently recognized form of cardiomyopathy. Also
referred to as left ventricular hypertrabeculation, LV myocardium in these patients shows
increased trabeculation, unlike normal compact structure of the LV. Imaging with echocar‐
diography or cardiac MRI, showing thick endocardial noncompact layer of myocardium and
relatively thin epicardial compact myocardium, usually makes the diagnosis. Apart from heart
failure and thromboembolic events, patients with ventricular noncompaction are known to be
at an increased risk of sudden cardiac death due to ventricular arrhythmias. Life-threatening
ventricular tachycardias are reported in almost one fifth of the patient. The arrhythmogenic
substrate is in the form of subdendocardial fibrosis due to microcirculatory dysfunction (figure
5). [30], [31]
3.6. Other cardiomyopathies
Sarcoidosis frequently involves the myocardium, causing infiltration and scarring. Although
at least 25% of patients with sarcoidosis have cardiac involvement based on autopsy data, only
5% have cardiac symptoms. Patients with sarcoid cardiomyopathy are at an increased risk of
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developing a conduction system abnormality due to involvement of basal part of the inter‐
ventricular septum and this may result in complete heart block [32], [33] and potentially
sudden cardiac death. Ventricular arrhythmia is another mechanism of sudden cardiac death
in patients with cardiac sarcoidosis. Resolving inflammation and resulting scarring of the
myocardium provides substrate for reentrant ventricular arrhythmias. [34], [35]
Cardiac amyloid infiltration is another disorder associated with increased risk of sudden
cardiac death. Amyloid infiltration with perivascular fibrosis and small vessel ischemia [36]
is instrumental in pathology of cardiac conduction system and myocardium. These patholog‐
ical changes lead to the electrophysiological abnormalities responsible for sudden cardiac
Figure 4. Photomicrographs of the myocardium from a 35-year-old female. (A) Shows evidence of myofibre hypertro‐
phy, interstitial fibrosis (*) and areas of lymphocytic infiltration (arrows) consistent with resolving myocarditis (H&E).
(B) While some myocytes are hypertrophied with enlarged nuclei (black arrow), others are thinned and elongated
with nuclei that occupy almost the entire width of the myocyte (white arrow). Some myocytes appear “empty”; likely
due to diminished numbers of myofibrils. Areas of interstitial fibrosis (*) and fat infiltration (F) can also be seen (H&E).
(C) Photomicropgraph showing evidence of interstitial fibrosis (*), subendocardial fibrosis (arrows) and endocardial fi‐
broelastic changes (arrowheads) (H&E). (D) Microphotograph of myocardium showing degenerative changes in the
left bundle (dotted line). These changes may appear as a bundle branch block on ECG. Areas of interstitial fibrosis (*)
and lymphocytic infiltration (arrows) are also seen (elastic trichrome stain). Adapted with permission from Luk et al,
Dilated cardiomypathy : a review. J Clin Pathol 2009;62:219-225.
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death due to bradyarrhythmia or ventricular tachyarrhythmia. [37] Frequently the cause of
sudden death in these patients is pulseless electrical activity, presumably resulting from the
severe diastolic dysfunction associated with amyloidosis. [38]
Inherited muscular dystrophies like Duchenne and Becker muscular dystrophies have skeletal
and cardiac muscle involvement and cardiac pathology essentially manifests as dilated
cardiomyopathy with associated heart failure and risk of sudden cardiac death. However,
muscular dystrophies like Emery-Dreifuss (X-linked and autosomal variants), limb girdle
muscular dystrophy type 1B, entity of DCM with conduction system disease (associated with
lamin A/C mutations) and myotonic dystrophy are associated with high risk of sudden cardiac
death. In these conditions sudden cardiac death was traditionally thought to be primarily due
to conduction system disease and bradyarrhythmia. However, after routine implantation of
pacemakers, it has been recognized that ventricular arrhythmias also contribute to sudden
cardiac death in these patients. These conditions are associated with cardiomyopathy, with
LV dysfunction as a late feature in the natural course of disease; sudden cardiac death is an
early feature of cardiac involvement. The molecular pathogenesis of cardiac arrhythmias and
conduction system disease in these patients is an area of active research. [39]
4. Risk of sudden cardiac death in cardiomyopathy: Epidemiology and risk
stratification
The epidemiologic risk of sudden cardiac death in cardiomyopathy is often difficult to assess
because it is frequently impossible to determine the size of the population at risk. Determina‐
tion of risk is skewed by referral bias. The risk of sudden death has been studied with these
Figure 5. Photomicrographs of myocardium from a patient with LV noncompaction. Panel A shows low-power hema‐
toxylin- and eosin-stained photograph from noncompacted layer shoing ‘fingerlike’ projections. Panel B has a photo‐
micrograph with Masson’s t trichrome stain showing prominent endocardial and subendocardial fibrosis, which is a
feature of this disease due to abnormal myocardial microperfusion. Adapted from chapter ‘Cardiomyopathy’ by
Sian Hughes from the book ‘Cardiac Pathololgy: A Guide to Current Practice’ eds’ S. Kim Suvarna ISBN:
978-1-4471-2406-1 (Print) 978-1-4471-2407-8 (Online) (Springer).
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limitations in several groups of patients, most notably in those with ICM but also in hyper‐
trophic cardiomyopathy and arrhythmogenic cardiomyopathy. Attempts to identify features
predicting higher risk of sudden cardiac death have helped in management decisions. In this
section we will discuss available knowledge about risk of sudden death and risk stratification
in patients with cardiomyopathy.
Hypertrophic cardiomyopathy Dilated cardiomyopathy
Major risk factors
· Prior cardiac arrest
· Spontaneous sustained VT
· Family history of 1 or more
· instances of SCD
· Nonsustained VT (≥3consecutive beats at ≥120 bpm)
· Failure of systolic BP to rise by ≥20 mm Hg during maximal
upright exercise testing
· Unexplained syncope
· Maximum LV wall thickness ≥30 mm
Other risk factors
· Resting LV outflow tract
· obstruction
· Microvascular ischemia
· Diffuse late gadolinium
· enhancement on cardiovascular
· magnetic resonance
· Paced electrogram fractionation
· analysis
· Prior alcohol septal ablation
· Burnt out disease
· High-risk mutation
· Prior cardiac arrest
· Left Ventricular systolic function
· History of syncope
· Genetic factors
· NYHA functional class
· Prolongation of QRS
· QT dynamicity
· QRS fragmentation
· Heart rate variability, heart rate turbulence and
heart rate recovery,
· Baroreflex sensitivity
· T-wave alternans
· Myocardial fibrosis: serum markers, cardiac MRI
Ischemic cardiomyopathy
· Prior cardiac arrest outside the setting of acute
coronary syndrome
· LV systolic function
· NYHA fuctional class
· QRS duration
· QT interval prolongation
· QT dispersion,
· T-wave alternans
· Abnormal SAECG
· Heart rate variability, heart rate turbulence and
heart rate recovery,
· Baroreflex sensitivity
Arrhythmogenic right ventricular cardiomyopathy
· Prior cardiac arrest
· History of syncope
· RV dilatation/dysfunction
· LV involvement
· QRS dispersion
· Right precordial QRS prolongation and late potentials on SAECG
Table 1. Risk predictors for SCD in cardiomyopathies
Sudden Cardiac Death
http://dx.doi.org/10.5772/55636
175
4.1. Ischemic cardiomyopathy
Attempts at risk stratification for SCD initially included patient with history of myocardial
infarction and LV systolic dysfunction emerged as the strongest predictor of overall mortality
and SCD in them. [40]-[45] Many other potential risk factors have been studied, but LVEF
remains the strongest and most widely used predictor of SCD risk. ICD trials for prevention
of SCD have established the role of LV systolic function as the most important risk predictor.
Other important predictors of SCD in these patients include electrocardiographic parameters,
functional class, inducibility of ventricular arrhythmia with programmed ventricular stimu‐
lation, autonomic and neuro-humoral predictors and disturbances in autonomic innervation
of the myocardium.
1. LV systolic function emerged from studies in post-MI patients as a predictor of SCD. An
analysis of 20 studies found the relative risk of a major arrhythmic event in patients with
LVEF≤30% to 40% to be 4.3. [46] The Second Multicenter Automatic Defibrillator Implan‐
tation Trial (MADIT-II) and the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT)
clearly demonstrated the benefit of ICD implantation in patients with LVEF less than 30%
or 35% respectively in preventing sudden death and reducing absolute mortality in
patients with history of myocardial infarction. [47], [48]
2. Functional class is a surrogate of severity of heart failure and heart failure severity
predisposes to arrhythmogenesis by neuro-humoral mechanisms and homeostatic and
hemodynamic changes. NYHA class has been used as criterion to enroll patients in the
ICD trials and some of these studies have found its predictive value. Subgroup analysis
of SCD-HeFT enrolling patients with congestive heart failure with either ischemic or
nonischemic cardiomyopathy showed that patients with NYHA class III did not appear
to benefit as opposed to patients with NYHA class II. [48] On the other hand in MADIT-
II patients, there were no significant differences in the outcomes based on NYHA class.
[47] NYHA functional class III was found to be the strongest independent predictor of
ICD therapy in the Trigger Of Ventricular Arrhythmia (TOVA) trial. [49]
3. Programmed ventricular stimulation with inducible VT/VF has been recognized as a
predictor of sudden cardiac death in patients with history of myocardial infarction.
MADIT-I study which included patients with inducible VT/VF and LVEF ≤ 35% showed
a 26% absolute reduction in mortality at 27 months follow-up. [50] The reduction in
mortality was much lower at 6-7% absolute reduction in mortality in patients with
MADIT-II trial which enrolled patients with LVEF ≤ 30% and in a mixed population of
ischemic and nonischemic cardiomyopathy patients in SCD-HeFT enrolling patients with
LVEF ≤ 35% without electrophysiological assessment of inducibility. [47], [48] The
Multicenter UnSustained Tachycardia Trial (MUSTT), enrolling patients with LVEF≤40
and inducible VT on invasive assessment showed similarly high absolute reduction in
mortality of 31% at five years of follow up. [51]
4. Ventricular ectopy and NSVT has been shown to increase the risk of sudden cardiac death
in patients with history of MI in multiple studies. In the early observational studies from
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1970s and 1980s, VPBs (≥10 per hour) and NSVT in post-MI patients showed increased
risk of overall mortality. [40], [42], [52], [53] Similar effect of ventricular ectopy and NSVT
in post-MI patients has also been seen in the era of thrombolytic therapy for acute MI. [45],
[54]-[57] GISSI-2 trial showed a mortality of 5.5% at six months after MI in patients with
more than 10 VPBs per hour compared to 2% in those with less frequent VPBs. [57] Positive
predictive value of VPBs in predicting cardiac arrhythmic events is in the range of 5% to
15% with negative predictive value of in the range of 90%. [58] However, when combined
with LV ejection fraction, ventricular ectopy becomes a stronger risk predictor of SCD in
post-MI patients. In European Myocardial Infarction Amiodarone Trial (EMIAT), post-
MI patients with LVEF ≤ 40% had higher mortality in the presence of frequent or complex
arrhythmias on ambulatory ECG than in their absence (20% vs. 10%). [59] Moreover,
MADIT-I and MUSTT enrolled patients based on the presence of NSVT and showed
benefit in terms of reduction in all-cause mortality and SCD with ICD, all these patients
had to have inducible ventricular arrhythmia for being enrolled into the study. [50], [51]
5. Electrocardiographic parameters have been studied in multiple studies and can be divided
into parameters assessing ventricular conduction abnormality and parameters of ventric‐
ular repolarization abnormality. Parameters of conduction abnormality including QRS
duration, abnormalities on signal averaged ECG, and fractionation of QRS have been
studied in many studies. Parameters of repolarization abnormality including QT interval
prolongation, QT dispersion, T wave variance, QT dynamics, QT/RR slope and T-wave
alternans have all been studies in many studies. Each of these parameters confer a small
risk of sudden cardiac death individually. [60]-[62]
6. Parameters of autonomic function include heart rate variability, heart rate turbulence, baro-
receptor sensitivity and deceleraltion capacity. These again have been found to increase
the risk of sudden death in patients history of myocardial infarction with in many small
studies. [60]-[62]
7. Myocardial scar is instrumental in the pathogenesis of ventricular tachycardia by providing
the substrate for reentry circuit. Myocardial scar area assessed by cardiac MRI has been
demonstrated to be a predictor of inducible VT on electrophysiological study. [3] More‐
over, heterogeneity of scar in the border zone of infarct can be assessed by MRI and has
been shown to be a predictor of inducible and spontaneous ventricular arrhythmias. [63],
[64]
8. Cardiac autonomic denervation has been suggested a potential risk for arrhythmogenesis in
post-MI patients. Although denervation of peri-infarct tissue was found to be a risk factor
for inducible ventricular arrhythmia in animal model, [65] it failed to show any value in
a small clinical study. [66] However, a study in a population of heart failure patients
including both ischemic and nonischemic cardiomyopathy, showed increased risk of
ventricular arrhythmia with disturbances in myocardial innervation assessed by mIBG
scintigraphy. [67]
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9. Combinations of risk factors: As individual risk factor are not strong enough to predict SCD
and probably in isolation do not justify the use of ICD therapy to prevent SCD with the
current level of evidence, there has been an attempt to combine multiple risk factors to
create a model to enhance the predictability of SCD. Although there are multiple small
studies combining various risk factors to achieve the goal of refining the risk stratification
strategy, there is a need to assess these risk models in a prospective manner. [61], [68]
Study Patient population
LVEF of
enrolled
patients (%)
All-cause mortality (%) Risk reduction (%)
Control ICD Relative Absolute
Primary prevention ICD trials
AVID VFib, VT with syncope, VT with EF≤40% 32 25 18 27 7
CIDS
VFib, out-of-hospital cardiac arrest
due to VFib or VT, VT with syncope,
VT with symptoms and EF ≤35%,
unmonitored syncope with
subsequent spontaneous or induced
VT
34 21 15 30 6
CASH VFib, VT 46 44 36 23 8
Primary prevention ICD trials
MADIT
Prior MI, EF ≤35%, N-S VT, inducible
VT non-suppressible with IV
procainamide
26 32 13 59 19
CABG Patch Coronary bypass surgery, EF <36%,SAECG (+) 27 18 18 - -
MUSTT CAD (prior MI ~95%), EF ≤40%, N-SVT, inducible VT 30 55 24 58 31
MADIT II Prior MI (>1 month), EF ≤30% 23 22 16 28 6
DEFINITE Nonischemic CM, Hx HF, EF ≤35%,≥10 PVCs/hr or N-S VT 21 14 8 44 6
DINAMIT
Recent MI (6-40 days), EF ≤35%,
abnormal HRV or mean 24-hr heart
rate >80/min
28 17 19 - -
SCD-HeFT Class II-III CHF, EF ≤35% 25 36 29 23 7
Table 2. ICD trials
Cardiomyopathies178
4.2. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is frequently complicated by sudden cardiac death, and SCD
in, for example, athletes is frequently caused by HCM. This being said, early estimates of the
gravity of the prognosis of HCM were probably driven by referral bias of difficult cases to
specialist centers, and studies of more inclusive cohorts of patients indicate a much more
favorable prognosis. [69] A study by Maron et al analyzing a cohort of 774 non-referral-based
HCM patients showed an incidence of SCD of 0.7% per year. [70] They showed that although
SCDs occur across the age groups in patients with HCM, there are two peaks of SCD risk during
life, one in the early childhood and the other later in older age group in seventh and eighth
decades of life.
Several risk factors associated with SCD in HCM have been identified and it is important to
recognize this high-risk subset of patients for management strategies and prognostication.
1. History of syncope: In patients with HCM syncope is an important predictor of SCD. This
has been confirmed by multiple survival studies and a systematic review of 11 survival
studies. [71] Five of these survival studies showed a significant association between
history of syncope and SCD in these patients. [72]-[76] and in the systematic review the
hazard ratio was 2.68 (95% CI 0.97-4.38) for SCD. This association is clinically important
and a history of syncope in a HCM patient is worrisome and should prompt further
intensive investigation.
2. Non-sustained ventricular tachycardia (NSVT) with ≥3 consecutive ventricular beats at a rate
of 120 beats per minute lasting for <30 seconds has been shown to be significantly
associated with SCD in patients with HCM. [73], [77]-[79] The systematic study evaluating
the risk of SCD with NSVT showed a hazard ratio of SCD of 2.89 (95%CI 2.2-3.6). [71] The
risk of SCD associated with NSVT is lower in patients with older age (31-75 years), whereas
younger patient (14-30 years of age) have more than a four-fold increased risk of SCD (HR
4.35, 95% CI1.54-12.28). [77]
3. Severe left ventricular hypertrophy (LVH) has been found to be a predictor of sudden cardiac
death in multiple studies. [8], [72], [77], [80]-[82]In a recent systematic review the risk of
SCD was found to be three-fold (hazard ratio 3.1, 95%CI 1.81-4.4) despite variable
definitions. [71] Although most of the studies used a cut off for maximum wall thickness
of ≥30 mm, there has been concern about variability in measurement across the studies
and lack of data about pattern of LVH. One study used Wigle scores, a semi-quantitative
scoring system described earlier, [83] for LVH severity and showed increased risk of SCD
with increasing Wigle score. [81]
4. Family history of SCD and Genetic markers: Familial association of SCD has been described
in patients with HCM in early studies. [84]-[86] A systematic review of survival studies
showed an increased risk of SCD in patients with family history of SCD with hazard ratio
of 1.27(95%CI 1.16-1.38) [71]Family members tend to share genetic abnormality, and
certain specific genetic mutations have been associated with higher risk of SCD. For
example, troponin T mutations have been reported to have association with high risk of
SCD, often disproportionate to the other phenotypic expression. [87]
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5. Left ventricular outflow tract obstruction (LVOTO): The severity of the dynamic LVOTO is
associated with an increased risk of SCD. The mechanism of this could be reduction of
cardiac output and electromechanical dissociation, but myocardial ischemia induced by
increased ventricular stress is also of possible etiologic significance. An instantaneous
pressure gradient of 50 mmHg across the LVOT is considered to be clinically significant.
Five studies have shown significant association between LVOTO and SCD in patients with
HCM. [73], [76], [79], [88]
6. Systolic blood pressure response to exercise is altered in many patients with HCM probably
due to decreased systemic vascular resistance. [89] Sadoul et al demonstrated in 161 HCM
patients ≤40 years old that failure of systolic blood pressure to rise ≥20 mmHg during
exercise or a fall of >20 from the peak systolic blood pressure was associated with an
increased risk of SCD (15% vs 3%, p<0.009). [90] However, analysis of multiple survival
studies with data from a wider age range did not confirm this association (hazard ratio
1.23, 95%CI 0.64-1.96) [71] but four of these studies did show abnormal systolic blood
pressure response to be a risk factor for SCD in subjects ≤40 years old. [73], [76], [77], [80]
7. Other factors: Atrial fibrillation and left atrial size may reflect the risk of SCD as they reflect
the severity of left ventricular pathology. [74], [91] NYHA functional class is also a function
of diastolic dysfunction, myocardial ischemia, LVOTO, atrial arrhythmias and adverse
remodeling, and potentially can be associated with SCD, but studies reporting survival
analysis for SCD did not report any significant association. Late gadolinium enhancement
on MRI, which is suggestive of presence of extracellular myocardial collagen deposition
and a potential substrate for ventricular arrhythmias, was not associated with SCD in a
recent study, although it was associated with cardiovascular morbidity and mortality. [10]
Increased fractionation of the paced right ventricular electrogram at invasive electrophy‐
siological study has been found to be associated with SCD in patients with HCM and this
is presumably a reflection of myofibrillar disarray. HCM patients with LV systolic
dysfunction should be considered at a higher risk of SCD similar to other causes of LV
systolic dysfunction. Age of the patient modifies the risk of SCD in patients with HCM as
suggested by multiple studies with higher risk in adolescence and early adulthood. The
survival study by Spirito et al showed a significant reduction in SCD risk with increasing
age, however, this study did not include other established risk factors in multivariate
analysis.[74]
4.3. Arrhythmogenic cardiomyopathy
Ventricular arrhythmia, principally VF is the mode of SCD in patients with arrhythmogenic
cardiomyopathy. The absolute risk of SCD in a patient with ARVC has been reported, although
inconsistencies between different studies make it hard to establish the degree of risk. The
annual risk of SCD in studies from the pre-ICD era in high-risk cohorts was in the range of
1-1.5%. [92]-[94] Sports activity increases the risk of SCD by five fold. [95] Although more recent
follow-up studies of patients with ICDs have shown a higher annual rate of ICD intervention,
of 5-8%, [96], [97] an ICD intervention may not be a good surrogate for SCD. A follow-up study
of patients diagnosed on the basis of aggressive screening of the family members of the
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probands showed much lower annual incidence of SCD at 0.08% per year. [98] This suggests
a strong selection bias of high-risk patients in the previous follow-up studies and with current
approach of aggressive screening of the family members of probands; the previous estimates
of the degree of risk of SCD may not be applicable. Many studies have tried to establish
parameters to predict the risk of sudden death.
1. History of syncope has been documented as a precursor of SCD in multiple studies. [93] In
a study by Nava et al syncope was the only clinical variable predictive of SCD in probands,
while none of the family members of the proband had history of syncope. [98] The Darvin
II study and data from the Johns Hopkins arrhythmogenic cardiomyopathy clinic have
evaluated the importance of history of syncope in patients receiving ICD. The multi-center
Darvin II study showed that syncope is a strong predictor of life-saving device interven‐
tion in patients with ICD. In the Johns Hopkins cohort, although 75% of the patients with
AC receiving appropriate ICD therapy did not have history of syncope, one half of patients
with history of syncope prior to the implantation of ICD received appropriate ICD therapy
(9%/year). A recent history of syncope was even stronger predictor of appropriate ICD
therapy compared to remote history of syncope. [99]
2. Prior history of hemodynamically unstable ventricular arrhythmia or cardiac arrest is a strong
predictor of SCD. A history of arrhythmic cardiac arrest or hemodynamically unstable
VT, but not a history of hemodynamically stable VT, was found to be independent
predictor of life-saving ICD therapy in a study by Corrado et al. [96] In another study by
Canu et al with retrospective analysis of 22 patients, previous history of resuscitated VF
was present in two out of three patients who died suddenly. [100]
3. Electrocardiographic parameters including QRS dispersion, right precordial QRS prolonga‐
tion and late potentials on signal-averaged ECG (SAECG) have been found to be associ‐
ated with risk of SCD. Turrini et al demonstrated longer QRS duration in right precordial
leads in patients with SCD as compared to those without. [101] QRS dispersion of >40
msec was strong independent predictor of SCD in this study. Late potential on SAECG
have not been found to predict arrhythmic risk in these patients. [102]-[104] Although in
the study by Turrini et al late potentials were univariate predictors of sustained VT,
decreased RV ejection fraction remained the only independent predictor in multivariate
analysis. [104]
4. RV dilatation/dysfunction and LV involvement are important predictors of poor outcome
[105] and SCD [106] in arrhythmogenic cardiomyopathy. RV dysfunction has been
associated with increased risk of ICD discharges and sustained VT. [97], [104], [107] It is
not clear as yet if LV involvement detected by tissue characterization without LV dilata‐
tion or dysfunction increases the risk of SCD.
5. Other factors: Most of the genetic variants of arrhythmogenic cardiomyopathy have similar
risks of SCD. However a very malignant genetic variant with TMEM43 gene mutation
significantly increases the risk of SCD. [108] Studies evaluating the significance of
programmed ventricular stimulation as a predictor of SCD in the patients with arrhythmo‐
genic cardiomyopathy has shown mixed results. The DARVIN studies and the study by
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Wichter et al did not show any significant predictive value of programmed ventricular
stimulation in predicting ICD discharges. [96], [97], [109] Although the Johns Hopkins
study did show some relationship between programmed stimulation of ventricular
arrhythmia and later ICD shocks, the association did not confer good positive and
negative predictive values (65% and 75% respectively). [99] Hence, withholding ICD
therapy on the basis of negative EP study should not be recommended and other param‐
eters for risk stratification should be taken into consideration to make a decision for ICD
implantation.
4.4. Dilated cardiomyopathy
SCD in patients with dilated cardiomyopathy is one of the major causes of mortality, consti‐
tuting nearly one-third of all deaths. Left ventricular systolic function as determined by LVEF
and NYHA functional class have become the most extensively used variable to stratify risk of
SCD in this group of patients. Other parameters including a history of syncope, genetic factors
and programmed ventricular stimulation have been evaluated to stratify the risk of SCD in
these patients, and these are summarized below.
1. Left Ventricular systolic function is associated with increased overall mortality and SCD in
patients with nonischemic dilated cardiomyopathy. [110]-[112] This has been reaffirmed
by the reduction in SCD seen with ICD implantation in patients with NIDCM with LV
systolic dysfunction in DEFINITE and SCD-HeFT ICD trials. [48], [113]
2. NYHA functional class is important determinant of overall survival and SCD in patients
with systolic heart failure. [114] However, with worsening NYHA functional class, non-
sudden death becomes relatively more important in patients with heart failure compared
to SCD. Patients with NYHA class III were significantly more likely to receive ICD therapy
for ventricular arrhythmia even after adjusting for LVEF in TOVA study, however, there
were very few patients with NYHA class IV in this study. [49] NYHA class IV patients,
although at risk of arrhythmic death, are less likely to benefit from ICD due to competing
risk of non-sudden heart failure death. Majority of patients in the major ICD trials (SCD-
HeFT and DEFINITE) were class II and class III patients, and the reduction in SCD in these
groups of patients is well established. [48], [113] However, NYHA class I patients were
largely under-represented in majority of the ICD trials with the exception of DEFINITE
study which had 21.6% patients in NYHA class I.
3. History of syncope increases the risk of SCD in patients with heart failure with dilated
cardiomyopathy. In a SCD-HeFT sub-study patients with history of syncope had higher
frequency of receiving appropriate ICD therapy compared to those without a history of
syncope. Moreover, patients with history of syncope had similarly increased risk of
mortality in ICD (HR: 1.54, 95% CI 10.4-2.27), amiodarone (HR: 1.33, 95% CI 0.91-1.93) and
placebo (HR: 1.39, 95% CI 0.96-2.02) arms (p=0.86 for test of difference between the three
arms).
4. Genetic factors: There has been a recent recognition of certain genetic mutations associated
with increased risk of SCD in patients with dilated cardiomyopathy. For example, dilated
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cardiomyopathy associated lamin A/C gene (LMNA), which is also associated with
cardiac conduction defects, has been found to have particularly high risk of SCD. A
significant proportion of these patients received appropriate ICD therapy even before the
development of heart failure. [116], [117] These patients are at a higher risk of sudden
death with lower degree of LV systolic dysfunction and a recent study has suggested high
risk of malignant ventricular arrhythmia in patients who are male, have dilated LV, have
NSVT or LVEF < 45%. [118] SCN5A overlap syndrome with dilated cardiomyopathy are
at increased risk of SCD.
5. NSVTs and PVBs have not been found to have predictive value in of arrhythmic event in
patients with DCM. In medically stabilized patients Zecchin et al failed to show any
difference in arrhythmic event between patients with and without NSVTs. [119] NSVT
was not evaluated for prediction of SCD in the large primary prevention trial like
DEFINITE and SCD-HeFT, [48], [113]
6. Others factors: Electrocardiographic parameters have been evaluated to identify the groups
of dilated cardiomyopathy patients with risk of SCD. [120], [121] Prolongation of QRS
and presence of left bundle branch block are independent predictors of SCD. Parame‐
ters of QT dynamicity and QRS fragmentation may be useful in risk stratification of SCD.
[122],  [123] SAECG, heart  rate variability,  heart  rate turbulence,  heart  rate recovery,
baroreflex sensitivity and T-wave alternans have been evaluated and each individual
risk factor has a small effect size. [61], [62] As discussed earlier in the section on ischemic
cardiomyopathy, these ECG parameters and parameter of autonomic function have small
effect  when  used  individually  and  may  have  a  stronger  risk  predictive  value  in
combination. [61], [68] Assessment of myocardial fibrosis by various methods includ‐
ing serum markers of fibrosis and cardiac MRI with late gadolinium enhancement may
potentially become a tool in risk stratification for sudden cardiac death in patients with
dilated cardiomyopathy. [124]
4.5. Other cardiomyopathies
Left ventricular noncompaction is associated with left ventricular dysfunction and risk of
ventricular arrhythmia. Studies to assess the degree of risk and parameters to stratify the risk
have not been done in this group of patients, but it is noteworthy that the diagnosis has only
recently been recognized. LV systolic dysfunction may be a predictor of SCD in these patients,
although concerns have been raised about its value. [125] Any other parameter to stratify the
risk is still speculative.
Patients with cardiac sarcoidosis have poorer prognosis compared to idiopathic dilated cardio‐
myopathy with similar degree of LV systolic dysfunction. [126], [127] Patients ventricular
tachycardia or atrioventricular block are at a high risk of adverse cardiac events. Presence of
AV block in patients with cardiac sarcoidosis younger than 55 years increase the risk of adverse
cardiac outcomes over 2 years by ten-fold as compared to patients without cardiac sarcoidosis.
[32] Asymptomatic cardiac involvement in sarcoidosis has been largely reported to have
benign prognosis, [128]-[130] although one recent report recorded 19% mortality (5 out of 21
patients with MRI diagnosed cardiac sarcoidosis) over a follow-up period of 21 months. [131]
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Assessment of SCD risk in cardiac amyloidosis is not well defined. Little data is available on
risk stratification,  and the usual  approach in  these  patients  is  secondary prophylaxis  or
extrapolation of risk factors from other types of cardiomyopathies, e.g., LV systolic dysfunc‐
tion.  The degree of  myocardial  involvement  in  sarcoidosis  may be important  in  clinical
decision-making. Patients with hereditary dystrophies behave largely like dilated cardiomyop‐
athy and risk stratification in these patients again conforms to the risk stratification of dilated
cardiomyopathy.
5. Management
5.1. Pharmacotherapy and sudden cardiac death prevention
The role of pharmacotherapy in the prevention of SCD is two-fold. First, many neuro-humoral
modifiers for the treatment of heart failure result in reverse remodeling of the left ventricle
and may therefore reduce the overall mortality, and the risk of SCD. Examples include ACE
inhibitors, angiotensin receptor blockers, aldosterone antagonists and beta-blockers. Second,
antiarrhythmic medications have been used in patients with cardiomyopathy to reduce the
risk of SCD. Examples would be beta-blockers including sotalol, amiodarone and other
antiarrhythmic medications.
Amiodarone has been evaluated in large randomized trials in post-MI patients. The Canadian
amiodarone myocardial infarction arrhythmia trial (CAMIAT) conducted in 1202 post-MI
patients with a mean LVEF of 30% and greater than 10 PVC’s per hour demonstrated a small
but significant reduction in arrhythmic death (4.5% versus 6.9%, P = 0.016) but no reduction
in all-cause mortality in patients on amiodarone. [56] The European Myocardial Infarct
Amiodarone Trial (EMIAT) of 1486 similar patients did not show any difference in arrhythmic
or all-cause mortality between the two groups of patients. [59] A meta-analysis of 15 random‐
ized controlled trials in a total of 8522 patients that evaluated amiodarone for prevention of
SCD showed a small but significant reduction in SCD (7.1% vs 9.7%; OR 0.71, p<0.001) but no
important change in overall mortality. [132] In the general population of heart failure patients
the SCD-HeFT trial did not show any reduction in all-cause mortality with amiodarone
treatment in comparison with placebo. [48]
Sotalol a beta-blocker that is also a class III antiarrhythmic drug (i.e., prolongs QT interval) has
been studied for prevention of SCD in patients with post-MI LV systolic dysfunction with
mixed results. A study by Julian et al evaluated the role of racemic d,l-sotlol in 1456 patients
5-14 days after MI. Racemic sotalol exhibits both beta blocking properties (the l-isomer) and
class III antiarrhythmic effects (the d-isomer), and this combination showed a nonsignificant
reduction in mortality over one-year follow up. [133] By contrast, oral d-sotalol, in the SWORD,
trial showed increased mortality in 3121 patients with recent (6-42 days) MI or with remote
(>42 days) MI with symptomatic CHF with LVEF ≤40%. [134] This lack of benefit or actual
harm seen in SWORD trial may be due to lack of beta-blocking property of d-sotalol, which
probably led to some benefit seen in the study by Julian et al using racemic sotalol. [135] As a
result of the SWORD trial, d-sotalol was abandoned. On the other hand a multicenter placebo
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controlled trial in patients with ICD showed a reduction in mortality and ICD shocks in
patients receiving d,l-sotalol. Moreover, the mortality benefit in this study did not differ
between patients with LVEF <30% and >30%. [136]
Beta-blockers has a proven role in reducing cardiovascular mortality and SCD in patients with
heart failure either from non-ischemic cardiomyopathy or ischemic heart disease. [114], [137]-
[139] Similarly, ACE inhibitors, ARBs and aldosterone antagonist are used in heart failure
patients to reduce all-cause mortality, however, neither ACE inhibitors nor ARB actually
reduce SCD in patients with LV systolic dysfunction. [140]-[142] ELITE did show an unex‐
pected reduction of SCD with losartan but this was a non-prespecified endpoint and was never
confirmed prospectively. [143]
Class I antiarrhythmic drugs have not been found to reduce SCD in patients with history of
MI and LV systolic dysfunction, and in fact most often result in an increase in mortality. The
Cardiac Arrhythmia Suppression Trial (CAST) and CAST-II trials, for example, showed
increased mortality with the use of class Ic antiarrhythmic drugs in post MI patients. [144]
Similarly, propafenone showed increased mortality compared to ICD in Cardiac Arrest Study
Hamburg (CASH). [145]
As the data of ICD trials showed reduction in all-cause mortality and SCD in patients with
cardiomyopathy as compared to amiodarone, the role of antiarrhythmic drugs in prevention
of SCD has become adjunctive, with the goal of reducing ICD shocks. Beta-blockers and other
humoral modifiers are generally used in the management of heart failure and improve survival
in heart failure patients.
The role of amiodarone for prevention of SCD in HCM is controversial. In a study by McKenna
et al, [146] amiodarone found to be effective but it is noteworthy that this study was used
historical controls receiving either mexiletine, disopyramide or quinidine. In other studies
antiarrhythmic drugs for the prevention of SCD in HCM have not been found to be effective.
[147] Similarly, beta-blockers, sotalol and amiodarone have been used to suppress ventricular
arrhythmias in ARVC. Efficacy has been variable [148], [149] and, with the increasing practice
of use of ICD in the prevention of SCD in these patients, antiarrhythmic drugs are again used
to reduce the need for ICD intervention.
5.2. Device therapy: Implantable cardioverter-defibrillator
Implantable cardioverter-defibrillator therapy has emerged as the most important manage‐
ment strategy for prevention of SCD in patients with cardiomyopathy at high risk of sudden
cardiac death. The high incidence and high individual risk of SCD in cardiomyopathy patients
with impaired left ventricular function, especially in those who had survived a ventricular
arrhythmia, and the relative ineffectiveness of antiarrhythmic drugs in these patients led to a
series of trials aimed at assessing the role of ICD therapy. This strategy was first tested in trials
of patients with highest degree of risk. These were sudden death and ventricular arrhythmia
survivors, and the studies are collectively referred to as secondary prevention trials. These
trials were followed by trials of increasingly lower risk patients, principally those with heart
failure, in primary prevention trials. The major message of these trials is that cost effectiveness
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is highest in highest risk patients, but that in this group, numerically the number of lives saved
by defibrillators is relatively small. Use of defibrillators in lower risk cohorts decreases cost
effectiveness, but increases the chance of making a numerical impact of the incidence of SCD
in the contemporary US population.
5.3. Secondary prevention ICD trials
Antiarrhythmics versus implantable defibrillators (AVID), Canadian implantable defibrillator
study (CIDS) and Cardiac arrest study Hamburg (CASH) trials gave an insight into the benefits
of use of ICDs in secondary prevention of SCD after an arrhythmic event. In these studies
patients with history of aborted SCD or patients with ventricular arrhythmia in the setting of
reduced LV systolic function were enrolled.
The AVID trial, which enrolled 1016 patients with history of VF, VT with syncope or VT with
LVEF ≤40% and symptoms of hemodynamic compromise (near syncope, congestive heart
failure and angina). This study showed reduction in all-cause mortality from 25% to 18%
(absolute risk reduction of 7% and relative risk reduction of 27%). The patients had a mean
LVEF of 32% in this study. In each arm, 45% of the patients had history of VF and the rest of
the patients had history of VT as the inclusion criteria for the study. CIDS enrolled 659 patients
with VF, out of hospital cardiac arrest due to VF or VT, VT with syncope, VT with symptoms
of presyncope or angina and LVEF ≤35%, and unmonitored syncope with subsequent spon‐
taneous or induced VT. The mean LVEF in these patients was 34%. After follow-up of 3 years
there was a nonsignificant reduction in all-cause mortality (10.2% per year to 8.3% per year,
p=0.142), and of arrhythmic death (4.5% per year to 3.0% per year, p=0.094) in ICD patients.
At 2 years there was a reduction in all-cause mortality from 21% to 15% (absolute and relative
risk reduction of 30% and 6% respectively).
The CASH study was a much smaller study with enrollment of 191 patients with a history of
VF or VT without an identified transient reversible cause. In contrast to AVID and CIDS the
mean LVEF was 46% making them healthier group of patients. Over a mean follow-up of 57
months the reduction in mortality was from 44% in control to 36% in those receiving ICD
(absolute and relative risk reduction of 23% and 8% respectively). Overall survival was higher
in the ICD arm, though not statistically significant (hazard ratio 0.766, 97.5% CI upper bound
1.112; p=0.081). There was higher survival free of sudden death in the ICD arm (hazard ratio
0.423, 97.5% upper bound 0.721; p=0.005).
Thus the trials were consistent in their message although CASH and CIDS trials were relatively
underpowered to assess the reduction in all-cause mortality. A meta-analysis showed a 28%
relative reduction in all cause mortality and a 50% reduction in SCD in patients receiving ICDs.
[150] Patients with LVEF < 35% derived the most benefit with hazard ratio for this group of
0.66 (95% CI 0.53-0.83). [150] and overall the number needed to treat to save a life per year of
follow-up was 29. [151] When the individual trials are compared it is noteworthy that LVEF
was much higher in CASH, and that CIDS included a group of patients with unexplained
syncope and VT inducible at EP study. These factors are markers of a lower risk population
and reduced that trials’ ability to detect the benefit of ICDs in reducing all cause mortality.
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Later subgroup analysis of these studies showed that the benefit of ICD therapy was largely
restricted to patients with lower LVEF. A subgroup analysis of 396 patients in the AVID trial
with LVEF >35% failed to show any survival benefit.  In addition a smaller group of 140
patients in this study with LVEF <20% did not show statistically significantly survival benefit.
This was in contrast to the 473 patients with LVEF between 20% and 34% who had signifi‐
cantly  improved survival.  [152]  Similarly,  in  CIDS trial  the  benefit  of  ICD therapy was
restricted to the patients with higher risk features (age >70 years, LVEF <35% and NYHA
class III or IV). [153]
5.4. Primary prevention ICD trials
Primary prevention ICD trials in patients with heart failure due to ischemic and nonischemic
cardiomyopathies have provided insights into prevention of SCD in a larger group of patients
who are at a high risk of SCD based on epidemiological studies, but are at lower risk than
patients who have suffered a ventricular arrhythmia. These studies have played instrumental
role in formulation of guidelines for primary prevention of SCDs in patients with cardiomyo‐
pathies. The trials include MADIT (I and II), CABG Patch, MUSTT, DINAMIT, DEFINITE and
SCD-HeFT.
Multicenter Automatic Defibrillator Implantation Trial (MADIT-I) was the first trial evaluating the
efficacy of ICD on survival in patients with history ischemic heart disease. Patients with an
LVEF≤35%, non-sustained VT who also sustained VT induced at a ventricular stimulation
study and not suppressed by procainamide were randomized to receive best medical therapy
or an ICD. 196 of these very high-risk patients were enrolled and mean LVEF was 26%. All
cause mortality was reduced from 32% to 13% in the ICD group after 2 years, for a relative risk
reduction of 59% [50]
The Multicenter Unsustained Tachycardia Trial (MUSTT) trial recruited a lower risk IHD cohort,
with NSVT and a LVEF ≤40%. All patients underwent a ventricular stimulation study, and
those with inducible sustained ventricular tachycardia were randomized to receive either no
specific antiarrhythmic therapy or antiarrhythmic therapy (either an antiarrhythmic drug or
an ICD) guided by further ventricular stimulation studies. Patients not inducible into sustained
VT were followed in a registry. Among 704 enrolled patients, the median LVEF was 30%. In
comparison to controls, patient treated with antiarrhythmic drugs had an increase in overall
mortality (from 48% to 55%) whereas patients receiving ICDs all cause mortality improved
from 48% in controls to 24% in patients receiving ICD with absolute and relative risk reduction
of 24% and 50% in a 5 year analysis (figure 6). [51] Interestingly the cohort of patients not
inducible into VT who received no specific antiarrhythmic therapy had a significantly lower
mortality than patients who were inducible into sustained VT, but the absolute improvement
in mortality predicted by a negative EP study was small (absolute risk reduction and relative
risk reduction of 7%,and 25% at 2 years and 4% and 8.3% at 5 years). [154] This study was the
first to point out the limited value of ventricular stimulation studies in assessing SCD risk.
These studies have now largely been abandoned, and future ICD trials have concentrated on
wider, lower risk, patient cohorts.
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The MADIT II trial assessed the effect of an ICD in 1232 patients with prior myocardial
infarction (>one month) and LVEF ≤30%. In this study, mainly of long term infarct survivors,
mean LVEF was 23% and in the ICD group all-cause mortality was reduced at 16% compared
to 22% in the controls after 2-year follow up (absolute and relative risk reduction of 6% and
28% respectively, figure 7). [47] In this cohort of IHD patients without inducible VT the benefit
of an ICD was smaller, but the potential population of identified patients who could benefit
from ICD therapy is much wider.
Defibrillator use early after acute myocardial infarction trial: The DINAMIT trial evaluated the role
of ICD in potentially improving the survival of patients during acute phase of MI (6 to 40
days  after  MI)  with  reduced LVEF ≤35% and impaired  cardiac  autonomic  function,  as‐
sessed as impaired baroreflex sensitivity. During a mean follow-up of 21/2 years, there was
no reduction in overall mortality in these patients. Although there was a reduction in death
due to arrhythmia, the benefit was offset by death from non-arrhythmic causes. [155] These
data are challenging because the implication is that ICD implantation enhanced the risk for
non-arrhythmic death, principally death from heart failure. If the amount of right ventricu‐
lar pacing in the ICD group accounted for more than 5-10% of heart beats this is a plausi‐
Figure 6. MUSTT: Kaplan–Meier Estimates of the Rates of Overall Mortality According to Whether the Patients Re‐
ceived Treatment with a Defibrillator. The P value refers to two comparisons: between the patients in the group as‐
signed to electrophysiologically guided (EPG) therapy who received treatment with a defibrillator and those who did
not receive such treatment, and between the patients assigned to electrophysiologically guided therapy who received
treatment with a defibrillator and those assigned to no antiarrhythmic therapy. (From reference 51)
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ble mechanism because RV pacing in heart failure patients is known to exacerbate heart
failure mortality. [156]-[158]
Defibrillators in non-ishchemic cardiomyopathy: The DEFINITE trial investigated the benefit of
prophylactic ICD therapy in 458 enrolled patients with non-ischemic cardiomyopathy with
LVEF <36% and premature ventricular complexes or NSVT. The patients were mainly
symptomatic for heart failure with NYHA functional class of I-III and mean LVEF of the study
population was 21%. At two years, the mortality in ICD group was 8% compared to 14% in
the standard therapy group (absolute and relative risk reduction of 6% and 44% respectively).
However this reduction in overall mortality was not statistically significant with hazard ratio
of 0.65 among patients receiving ICD (95% CI 0.40-1.06). This difference reached statistical
significance in patients with NYHA class III in subgroup analysis and showed a relative risk
of death of 0.37 (95%confidence interval 0.15-0.90). Moreover, the difference in survival was
significantly more in males receiving ICD (HR 0.49, 95%CI 0.27-0.90; p=0.018). [113].
Sudden cardiac death in heart failure (SCD-HeFT) trial was conducted in patients with heart failure
due to ischemic or nonischemic cardiomyopathy with LVEF≤35% and with NYHA functional
class II-III. More than 2500 optimally medically managed patients were equally divided into
Figure 7. MADIT II: Kaplan–Meier Estimates of the Probability of Survival in the Group Assigned to Receive an Implant‐
able Defibrillator and the Group Assigned to Receive Conventional Medical Therapy. The difference in survival be‐
tween the two groups was significant (nominal P=0.007, by the log-rank test). (From reference 47)
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three groups: ICD, amiodarone and placebo. Mean LVEF was 25%; 52% of the patients had
ischemic cardiomyopathy and the remainder were non ischemic. All cause mortality at 5 years
in patients receiving ICD was 29% compared to 36% for the control with absolute and relative
risk reduction of 7% and 23%. Amiodarone arm did not show any significant reduction in risk
of death (HR: 1.06; 97.5% CI 0.86-1.30; p=0.53)(see figure 8). In subgroup analysis by type of
cardiomyopathy, reduction in the mortality risk were similar in both ischemic (HR: 0.79, 97.5%
CI 0.60-1.04) and nonischemic cardiomyopathy (HR: 0.73, 97.5% CI 0.50-1.07) patients with
ICD therapy compared to placebo, although the risk reduction did not reach a statistical
significance. NYHA class did affect the effect of amiodarone as well as ICD therapy compared
to placebo. Amiodarone was shown to increase the risk of mortality in NYHA class III by 44%
(HR: 1.44, 97.5 CI 1.05-1.97), which was not seen in patients with NYHA class II (HR: 0.85,
97.5% CI 0.65-1-11). Similarly, with ICD therapy, patients with NYHA class III did not get
mortaliy benefit (HR: 1.16, 97.5% CI 0.84-1.61) as opposed to patients with NYHA class II (HR:
0.54; 97.5% CI 0.40-0.74) [48]
Figure 8. SCD-HeFT: Kaplan–Meier Estimates of Death from Any Cause. (From reference 48)
A meta-analysis of the primary prevention trials in patients with low ejection fraction due to
coronary artery disease or dilated cardiomyopathy including eight trials and total of 5343
patients showed reduction of arrhythmic mortality (relative risk: 0.40; 95% CI: 0.27-0.67) and
all-cause mortality (relative risk: 0.73; 95% CI: 0.64-0.82). The benefit of ICD therapy was similar
in ischemic (relative risk: 0.67; 95% CI: 0.51-0.88) and non-ischemic (RR: 0.74; 95% CI: 0.59-0.93)
cardiomyopathies. [159] Another important issue is that the age of the people enrolled in the
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large ICD trials is considerably younger than the people frequently needing ICD implantation
in the current clinical practice. This issue has been addressed by two meta-analysis suggesting
benefit of ICD therapy in older patients. [160], [161] Another meta-analysis of primary
prevention ICD trials showed smaller benefit of ICD in women with dilated cardiomyopathy
compared to men. Although overall mortality in both the genders were similar (HR 0.96, 95%
CI 0.67-1.39), women received approprite therapy less frequently compared to men (HR 0.63,
95%CI 0.49-0.82) and hence received less benefit from defibrillator therapy. [162] This as well
as another meta-analysis of primary prevention ICD trials failed to show significant mortality
benefit of ICD in women. [162]
These ICD trials have established the role of ICDs in the primary and secondary prevention
of SCD in patients with non-ischemic and ischemic cardiomyopathy (figure 9). Left ventricular
ejection fraction has been recognized as the strongest risk stratifier and has been extensively
used in all the trials. Based on these studies guidelines have been formulated for the appro‐
priate indications of ICD therapy in these patients. The table 3 summarizes the guidelines for
implantation of ICD for prevention of SCD in these patients.
Figure 9. Major implantable cardioverter-defibrillator (ICD) trials. Hazard ratios (vertical line) and 95% confidence in‐
tervals (horizontal lines) for death from any cause in the ICD group compared with the non-ICD group. *Includes only
ICD and amiodarone patients from CASH. For expansion of trial names, see Appendix 3. CABG: coronary artery bypass
graft surgery; EP: electrophysiological study; LVD: left ventricular dysfunction; LVEF: left ventricular ejection fraction;
MI: myocardial infarction; N: number of patients; NICM: nonischemic cardiomyopathy; NSVT: nonsustained ventricular
tachycardia; PVCs: premature ventricular complexes; SAECG: signal-averaged electrocardiogram. (Adapted with per‐
mission from reference 165)
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Indication for ICD Level ofevidence
Class I
1
Patients who are survivors of cardiac arrest due to ventricular fibrillation or hemodynamically unstable sustained VT
after evaluation to define the cause of the event and to exclude any completely reversible causes.
A
2
Patients with structural heart disease and spontaneous sustained VT, whether hemodynamically stable or
unstable.
B
3
Patients with syncope of undetermined origin with clinically relevant, hemodynamically significant sustained VT or
ventricular fibrillation induced at electrophysiological study.
B
4
Patients with LVEF less than or equal to 35% due to prior myocardial infarction who are at least 40 days post–
myocardial infarction and are in NYHA functional Class II or III.
A
5
Patients with nonischemic dilated cardiomyopathy who have an LVEF less than or equal to 35% and who are in
NYHA functional Class II or III.
B
6
Patients with LV dysfunction due to prior myocardial infarction who are at least 40 days post–myocardial
infarction, have an LVEF less than or equal to 30%, and are in NYHA functional Class I.
A
7
Patients with nonsustained VT due to prior myocardial infarction, LVEF less than or equal to 40%, and inducible
ventricular fibrillation or sustained VT at electrophysiological study.
B
Class IIa
1 Patients with unexplained syncope, significant LV dysfunction, and nonischemic dilated cardiomyopathy. C
2 Patients with sustained VT and normal or near-normal ventricular function. C
3 Patients with hypertrophic cardiomyopathy who have 1 or more major† risk factor for SCD. C
4
Patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy who have 1 or more risk factor for
SCD.
C
5 Patients with long-QT syndrome who are experiencing syncope and/or VT while receiving beta blockers. B
6 Nonhospitalized patients awaiting transplantation. C
7 Patients with Brugada syndrome who have had syncope. C
8 Patients with Brugada syndrome who have documented VT that has not resulted in cardiac arrest. C
9
Patients with catecholaminergic polymorphic VT who have syncope and/or documented sustained VT while receiving
beta blockers.
C
10 Patients with cardiac sarcoidosis, giant cell myocarditis, or Chagas disease. C
Class IIb
1
Patients with nonischemic heart disease who have an LVEF of less than or equal to 35% and who are in NYHA
functional Class I.
C
2 Patients with long-QT syndrome and risk factors for SCD. B
3
Patients with syncope and advanced structural heart disease in whom thorough invasive and noninvasive
investigations have failed to define a cause.
C
4 Patients with a familial cardiomyopathy associated with sudden death. C
5 Patients with LV noncompaction. C
Class III
1
Patients who do not have a reasonable expectation of survival with an acceptable functional status for at least
1 year, even if they meet ICD implantation criteria specified in the Class I, IIa, and IIb recommendations above.
C
2 Patients with incessant VT or ventricular fibrillation. C
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Indication for ICD Level ofevidence
3
Patients with significant psychiatric illnesses that may be aggravated by device implantation or that may preclude
systematic follow-up.
C
4
NYHA Class IV patients with drug-refractory congestive heart failure who are not candidates for cardiac
transplantation or implantation of a CRT device that incorporates both pacing and defibrillation capabilities.
C
5
Syncope of undetermined cause in a patient without inducible ventricular tachyarrhythmias and without structural
heart disease.
C
6
Ventricular fibrillation or VT is amenable to surgical or catheter ablation (e.g., atrial arrhythmias associated with Wolff-
Parkinson-White syndrome, right ventricular or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence of
structural heart disease).
C
7
Patients with ventricular tachyarrhythmias due to a completely reversible disorder in the absence of structural heart
disease (e.g., electrolyte imbalance, drugs, or trauma).
B
Table 3. ACC/AHA/HRS guidelines for implantation of ICDs (2008): indications in bold fonts refer to the indications
for various cardiomyopathies.
5.5. Risk stratification of heart failure patients for sudden death prevention
As data has accumulated suggesting that a strategy of wide ranging ICD implantation in
patients with impaired left ventricular systolic function will result in improvements in sudden
cardiac death mortality, concerns have been raised about the relatively low incidence of life
saving therapies in implanted patients. For example in MADIT II 14% of patients received a
potentially life saving defibrillator shock, whilst in SCD-HeFT only 21% of patients received
appropriate ICD therapy. In addition it has frequently been noted that an appropriate shock
does not necessarily represent an aborted sudden death. These considerations have lead to
attempts to derive scoring strategies from the data sets in the large prospective trials to try to
identify patients at low risk of requiring device therapy – and those in whom device therapy
might be futile.
Data from the MADIT II study in chronic IHD suggested that in very high risk (VHR) patients
defined as those with a BUN ≥ 50 mg/dl, mortality was high at 50% in two years and was not
improved by ICD therapy. ICD implantation in this patient group appears to be unjustified.
Among non-VHR patients, SCD risk was to be increased with NYHA functional class >II, a
history of atrial fibrillation, QRS duration >120 ms, age >70 years and BUN >26 mg/dl and <50
mg/dl. Patients with none of these risk factors were at low risk of SCD, and had no benefit
from ICD therapy. Patients with one to two risk factors derived benefit from an ICD whereas
patients with three or more risk factors did not derive as much benefit and behaved like VHR
patients. [163] Similarly, analysis of data from the MUSTT study suggested LVEF alone was
of limited value to predict the risk of SCD in this patient group. [164] The concern about using
a binary cut off of LVEF in deciding on the advisability or otherwise of ICD therapy to reduce
the risk of SCD is that SCD risk is a continuous variable and predicted by more than LVEF
alone. Multiple factors predict SCD to some extent and hence a risk score based on multiple
risk factors may be a better predictor of SCD. However, it should be noted that the mutiple
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risk models have not been evaluated in a prospective study and are entirely data derived. [68]
This being said, it seems inevitable that the guidelines for the implantation of ICDs will be
refined in the future and that risk scores will be incorporated.
5.6. ICD in other forms of cardiomyopathies
Implantation of ICD in cardiomyopathy other than ischemic and non-ischemic dilated
cardiomyopathy is not supported by evidence from large ICD trials. The majority of patients
enrolled in the large ICD trials were post-MI patients with LV dysfunction and patients with
dilated non-ischemic cardiomyopathy. In other forms of cardiomyopathies, like hypertrophic
cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, sarcoidosis and other
infiltrative cardiomyopathies, secondary prevention of sudden cardiac death with ICD
implantation in survivors of SCD and in patients with history of sustained ventricular
tachycardia is generally accepted clinical practice. However, implantation of ICD for primary
prevention of SCD has remained an unsolved issue in these patients. This has become more
of an issue with development of more effective screening of family members, and pre-
participation screening of athletes. Risk stratification in them has been attempted for each of
these groups.
Primary prevention in patients with hypertrophic cardiomyopathy is guided by multiple risk
factors for sudden cardiac death as discussed above. These risk factors have been defined as
discussed earlier and include (1) a family history of premature HCM-related sudden death;
(2) a history of unexplained syncope; (3) multiple and/or prolonged runs of nonsustained VT
on serial 24-hour ambulatory ECG monitoring at heart rates ≥120 beats/min; (4) a hypotensive
or attenuated blood pressure response to exercise; and (5) massive left ventricular (LV)
hypertrophy (maximum wall thickness ≥30 mm). The ACC/AHA/ESC guidelines on sudden
cardiac death and ventricular arrhythmia recommend implantation of ICD in patients with
one or more of these risk factors, for the primary prevention of SCD. [165]
Primary prevention of SCD in arrhythmogenic right ventricular cardiomyopathy is also guided by
a set of high risk factors. A multicenter study evaluated the use of ICD for primary prophylaxis
of SCD in patients with ARVC with at least one risk factor for SCD. These included syncope,
NSVT, a malignant family history, and inducibility of ventricular arrhythmias with program‐
med ventricular stimulation. Over a mean follow-up of 58 months 25 of 106 patients received
appropriate ICD intervention. ACC/AHA/ESC guidelines considers secondary prevention of
SCD with AICD to be reasonable (class IIa) in patients with ARVC considered high risk due
to LV involvement, one or more affected family member with SCD, or undiagnosed syncope
when VT or VF has not been excluded as the cause of syncope, while receiving chronic optimal
medical therapy. [165] ACC/AHA/HRS guidelines for device therapy for arrhythmia lists
ARVC as reasonable indication for primary implantation of ICD in the presence of one or more
risk of SCD. [166]
In patients with left ventricular non-compaction, ICD implantation is generally performed for
secondary prevention and for primary prevention in the presence of LV systolic dysfunction.
Although patients with normal LV systolic function or mild LV systolic dysfunction may be
prone to SCD, [125] lack of data makes the decision ICD implantation in these patients difficult.
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In patients with sarcoidosis, cardiac involvement with history of spontaneous VT and/or
severe LV systolic dysfunction may warrant ICD therapy despite lack of prospective trials.
[165] Implantation of ICD in patients with sarcoidosis in the absence of LV systolic dysfunction
or history of ventricular arrhythmias remains controversial. The ACC/AHA/HRS guidelines
for device therapy lists cardiac sarcoidosis as reasonable indication for ICD implantation. [166]
The use of ICD to prevent SCD in patients with cardiac amyloidosis is not well accepted and
may not affect the outcome, although it can be used to bridge the patients to cardiac trans‐
plantation. [38], [165] Some of the muscular dystrophies with associated cardiomyopathy are
treated in a similar way as dilated non-ischemic cardiomyopathy from other causes.
5.7. Device therapy: Permanent pacemaker
Some cardiomyopathies are prone to cause conduction abnormalities. For example patients
with muscular dystrophy due to lamin A/C gene mutation are particularly prone to conduction
defect and atrioventricular block. The threshold for pacemaker implantation in these patients
is very low to prevent SCD. Similarly, infiltrative myocardial diseases such as sarcoidosis can
lead to heart block and SCD as a result of this. Other examples include myotonic muscular
dystrophy, where SCD can result both from ventricular arrhythmias and from complete heart
block.
6. Future directions
The prevention of sudden cardiac death in patients with cardiomyopathy has evolved
dramatically in recent years. With the increasing use of ICDs in conjunction with pharmaco‐
therapy for heart failure, large number patients have benefited from prevention of SCD.
However, risk assessment for SCD is still far from accurate and many patients receiving ICDs
ultimately will not use them. Although, attempts have been made to refine the risk stratifica‐
tion, the current risk stratification is insufficient at least for many kinds of cardiomyopathies.
Data from subgroup analysis do provide some parameters for refining risk stratification, but
testing them in a prospective study will be an expensive and time-consuming undertaking.
Risk stratification for less common forms of cardiomyopathy has not largely been possible.
Some newer parameters like genetic evaluation may help in refining the risk assessment in the
future as more data on genetic analysis in various forms of cardiomyopathy comes forth.
Finally, newer pharmacotherapy may help in reducing the risk of SCD in these patients.
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